-
公开(公告)号：US20240092794A1
公开(公告)日：2024-03-21
申请号：US18502780
申请日：2023-11-06
Applicant: AMGEN INC.
Inventor： Shon BOOKER , Matthew Paul BOURBEAU , John R. BUTLER , Sanne Ormholt Schroder GLAD , Brian Alan LANMAN , Patricia LOPEZ , Francesco MANONI , Liping H. PETTUS , Ian SARVARY , Nuria A. TAMAYO , Mikkel VESTERGAARD , Nicholas Anthony WEIRES
IPC: C07D491/06 , A61P35/00 , C07D471/06 , C07D471/16 , C07D491/16
CPC classification number: C07D491/06 , A61P35/00 , C07D471/06 , C07D471/16 , C07D491/16
Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure:
-
公开(公告)号：US20240101570A1
公开(公告)日：2024-03-28
申请号：US18255575
申请日：2021-11-22
Applicant: AMGEN INC.
Inventor： Albert AMEGADZIE , Diane Jennifer BEYLKIN , Shon BOOKER , Matthew Paul BOURBEAU , John R. BUTLER , Sanne Ormholt Schroder GLAD , Todd J. KOHN , Brian Alan LANMAN , Kexue LI , Qingyian LIU , Patricia LOPEZ , Francesco MANONI , Primali Vasundera NAVARATNE , Liping H. PETTUS , Rene RAHIMOFF , Nuria A. TAMAYO , Mikkel VESTERGAARD , Hui-Ling WANG , Nicholas Anthony WEIRES
IPC: C07D491/048 , A61K35/00 , C07D401/12 , C07D401/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D491/147 , C07D495/04 , C07D498/04 , C07D519/00
CPC classification number: C07D491/048 , A61K35/00 , C07D401/12 , C07D401/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D491/147 , C07D495/04 , C07D498/04 , C07D519/00
Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).
-
Patent Agency Ranking
公开(公告)号：US20230159510A1
公开(公告)日：2023-05-25
申请号：US17799077
申请日：2021-02-11
Applicant: AMGEN INC.
Inventor： Jennifer Rebecca ALLEN , Albert AMEGADZIE , Diane Jennifer BEYLKIN , Shon BOOKER , Matthew Paul BOURBEAU , John R. BUTLER , Michael J. FROHN , Sanne Ormholt Schroder GLAD , Birgitte Weinreich HUSEMOEN , Matthew R. KALLER , Todd J. KOHN , Brian Alan LANMAN , Kexue LI , Qingyian LIU , Patricia LOPEZ , Vu Van MA , Francesco MANONI , Jose MEDINA , Ana Elena MINATTI , Jorge PEIRO CADAHIA , Liping PETTUS , Alexander J. PICKRELL , Ian SARVARY , Nuria A. TAMAYO , Mikkel VESTERGAARD
IPC: C07D413/14 , C07D471/04 , C07D401/14 , C07D401/12 , C07D405/14
CPC classification number: C07D413/14 , C07D401/12 , C07D401/14 , C07D405/14 , C07D471/04
Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure: (I)
-
公开(公告)号：US20250122222A1
公开(公告)日：2025-04-17
申请号：US18695673
申请日：2022-08-10
Applicant: AMGEN INC.
Inventor： Michael M. YAMANO , Yunxiao LI , Primali Vasundera NAVARATNE , Jose M. MEDINA , Ning CHEN , Liping PETTUS , Rene RAHIMOFF , Xiaofen LI , John STELLWAGEN , Francesco MANONI , Kexue LI , Brian Alan LANMAN , Ryan Paul Wurz , Wei ZHAO , Huan RUI , Josephine ESHON
IPC: C07D519/00 , A61K31/519 , A61K31/5386 , A61K31/541 , A61K31/553 , A61K31/554 , C07D471/04
Abstract: The present disclosure provides compounds useful for the inhibition of KRAS. The compounds have a general Formula I: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
-
公开(公告)号：US20250034167A1
公开(公告)日：2025-01-30
申请号：US18695693
申请日：2022-08-10
Applicant: AMGEN INC.
Inventor： Michael M. YAMANO , Yunxiao LI , Primali Vasundera NAVARATNE , Jose M. MEDINA , Ning CHEN , Liping PETTUS , Rene RAHIMOFF , Xiaofen LI , John STELLWAGEN , Francesco MANONI , Kexue LI , Brian Alan LANMAN , Ryan Paul Wurz , Wei ZHAO , Huan RUI , Josephine ESHON
IPC: C07D519/00 , A61K31/519 , A61K31/55
Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula (I): wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
-
公开(公告)号：US20240417412A1
公开(公告)日：2024-12-19
申请号：US18695688
申请日：2022-08-10
Applicant: AMGEN INC.
Inventor： Brian Alan Lanman , Wei Zhao , Ryan Paul Wurz , Primali Vasundera NAVARATNE , Liping PETTUS , Michael M. YAMANO , Ning Chen , Rene RAHIMOFF , Francesco MANONI , John STELLWAGEN
IPC: C07D519/00 , A61K31/519 , A61K31/5377 , A61K31/553
Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
-
公开(公告)号：US20220194955A1
公开(公告)日：2022-06-23
申请号：US17552016
申请日：2021-12-15
Applicant: AMGEN INC.
Inventor： Shon BOOKER , Matthew Paul BOURBEAU , John R. BUTLER , Sanne Ormholt Schroder GLAD , Brian Alan LANMAN , Patricia LOPEZ , Francesco MANONI , Liping H. PETTUS , Ian SARVARY , Nuria A. TAMAYO , Mikkel VESTERGAARD , Nicholas Anthony WEIRES
IPC: C07D491/06 , C07D491/16 , C07D471/06 , C07D471/16 , A61P35/00
Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure:
-
-
-
-
-
-
Search Results
7
records
(took 0.011 seconds)
